We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has GSK (GSK - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
GSK is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GSK is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for GSK's full-year earnings has moved 5.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that GSK has returned about 15.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 6.5% on average. As we can see, GSK is performing better than its sector in the calendar year.
Another stock in the Medical sector, Amarin (AMRN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.4%.
For Amarin, the consensus EPS estimate for the current year has increased 34.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, GSK belongs to the Medical - Biomedical and Genetics industry, a group that includes 505 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have lost 5.4% this year, meaning that GSK is performing better in terms of year-to-date returns. Amarin is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to GSK and Amarin as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has GSK (GSK - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
GSK is a member of the Medical sector. This group includes 997 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GSK is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for GSK's full-year earnings has moved 5.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that GSK has returned about 15.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 6.5% on average. As we can see, GSK is performing better than its sector in the calendar year.
Another stock in the Medical sector, Amarin (AMRN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 16.4%.
For Amarin, the consensus EPS estimate for the current year has increased 34.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, GSK belongs to the Medical - Biomedical and Genetics industry, a group that includes 505 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have lost 5.4% this year, meaning that GSK is performing better in terms of year-to-date returns. Amarin is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to GSK and Amarin as they could maintain their solid performance.